Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record.

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I‐meta‐iodobenzylguanidine (131I‐mIBG)

Mukherjee, J. J., Kaltsas, G. A., Islam, N., Plowman, P. N., Foley, R., Hikmat, J., Britton, K. E., Jenkins, P. J., Chew, S. L., Monson, J. P., Besser, G. M., Grossman, A. B.·2001·Clinical Endocrinology

Abstract

OBJECTIVE Meta‐iodo‐benzyl‐guanidine labelled with 131‐iodine (131 I‐mIBG) has been used extensively for imaging tumours originating from the neural crest but experience with its therapeutic use is limited, particularly for non‐catecholamine secreting tumours. In order to assess the therapeutic response and potential adverse effects of the therapeutic administration of 131 I‐mIBG, we have reviewed all patients who had received this form of treatment in our department. DESIGN Retrospective analysis of the case notes of patients with neuroendocrine tumours who received treatment with 131 I‐mIBG and were followed‐up according to a defined protocol in a given time frame. PATIENTS Thirty‐seven patients (18 with metastatic carcinoid tumours, 8 metastatic phaeochromocytoma, 7 metastatic paraganglioma and 4 metastatic medullary carcinoma of the thyroid) treated with 131 I‐mIBG over a 15‐year period were included in this analysis. MEASUREMENTS The symptomatic, hormonal and tumoural responses before and after 131 I‐mIBG therapy over a median follow‐up duration of 32 months (range 5–180 months) were recorded. Of the 37 patients (22 males; median age 51 years, range 18–81 years), 15 were treated with 131 I‐mIBG alone whereas the other 22 received additional therapy. RESULTS A total of 116 therapeutic 131 I‐mIBG doses were administered [mean cumulative dose 592 mCi (21·9 GBq); range 200–1592 mCi (7·4–58·9 GBq)]. None of the patients showed a complete tumour response. However, 82% of patients treated with 131 I‐mIBG alone and 84% who received additional therapy showed stable disease over the period of follow‐up. Overall survival during the period of the study was 71%. The overall 5‐year survival rate was 85% (95% confidence interval, 72–99%) for all patients and 78% (95% confidence interval, 55–100%) for the carcinoid group alone, according to Kaplan–Meier analysis. Symptomatic control was achieved in all the patients treated with 131 I‐mIBG alone, and in 72% of those receiving additional therapy. Hormonal control was noted in 50% and 57% of patients, respectively. 131 I‐mIBG therapy was safe and well tolerated. Serious side‐effects necessitating the termination of 131 I‐mIBG therapy were seen in only 2 of our patients. CONCLUSIONS 131 I‐mIBG therapy produces symptomatic and hormonal improvement and moderate tumour regression/stabilization in patients with metastatic neuroendocrine tumours with minimal adverse effects. It may be a valuable alternative or additional therapeutic option to the currently available conventional treatment modalities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2265.2001.01309.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 167

Metadata

Authors
Mukherjee, J. J., Kaltsas, G. A., Islam, N., Plowman, P. N., Foley, R., Hikmat, J., Britton, K. E., Jenkins, P. J., Chew, S. L., Monson, J. P., Besser, G. M., & Grossman, A. B.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2001-07
Volume
55
Issue
1
Pages
47-60
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2055454912
Cited by
167
References
0
FWCI
7.61
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I‐meta‐iodobenzylguanidine (131I‐mIBG). https://app.cochat.ai/papers/10.1046/j.1365-2265.2001.01309.x
The paper
Mukherjee, J. J., Kaltsas, G. A., Islam, N., Plowman, P. N., Foley, R., Hikmat, J., Britton, K. E., Jenkins, P. J., Chew, S. L., Monson, J. P., Besser, G. M., & Grossman, A. B. (2001). Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I‐meta‐iodobenzylguanidine (131I‐mIBG). Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2001.01309.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.